Alternatively, CD163 as a marker of immunosuppressive myeloid cells in tumor may not be sensitive enough to detect the diverse myeloid populations in the brain and could be underestimating or reflecting only a small subset of myeloid cells (48, 49). This evidence concerns the gene CD163 and neoplasm.